Managing HIV/AIDS Therapy in Treatment-Experienced Patients Are once-daily regimens just as potent as twice-daily regimens?
	Enlarged Version of Graphics Below	Dr. Bellos (OC): Yes, they are. If you look at the drugs we are currently using once daily, I do think that their potency is equivalent. Dr. Bellos (VO): We have data to support that. For example, with abacavir/3TC, with tenofovir/3TC or tenofovir/FTC, we do have potency data and durability data on those patients to show that even with these once a day agents, we do have significant benefits long term.   See Slide Dr. Wohlfeiler (OC): I think that they are. There's always this talk about forgiveness quotient. But medications that are designed to be administered once a day should have a forgiveness probably that's appropriate to that dosing interval. The other thing is that in my experience patients don't tend to forget for 24 hours at a time. They tend to forget for 12 hours or something. And so often they don't go 24 or 48 hours without taking a dose if they've just forgotten. So I think that this should be really pretty much as effective as twice-daily regimens. Dr. Kwakwa (OC): Well, the concern is that the pharmacokinetic cushion with the once a day regimen, toward the end of that 24-hour period, may not be as great as it is for the twice a day regimen toward the end of that 12 hour period. Is it adequate for most patients? Absolutely, but then, there isn't that level of comfort, that cushion, that you may see with twice a day.
Program Menu	Last   |	Next